SG Americas Securities LLC Sells 10,881 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

SG Americas Securities LLC reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 39.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,888 shares of the company’s stock after selling 10,881 shares during the period. SG Americas Securities LLC’s holdings in Elanco Animal Health were worth $248,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. raised its position in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Partners LLC bought a new position in Elanco Animal Health during the 2nd quarter worth $31,000. nVerses Capital LLC bought a new position in Elanco Animal Health during the 2nd quarter worth $32,000. Quarry LP bought a new position in Elanco Animal Health during the 2nd quarter worth $40,000. Finally, Global Financial Private Client LLC bought a new position in Elanco Animal Health during the 1st quarter worth $72,000. 97.48% of the stock is owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was acquired at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Jeffrey N. Simmons purchased 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. This trade represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ELAN. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Barclays lifted their price objective on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. Finally, Piper Sandler lowered their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.43.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $12.63 on Tuesday. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of -4.76, a PEG ratio of 1.53 and a beta of 1.40. The business has a 50-day simple moving average of $14.47 and a 200 day simple moving average of $14.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the company posted $0.18 EPS. The firm’s revenue was up 12.0% compared to the same quarter last year. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.